Annual report pursuant to Section 13 and 15(d)

Consolidated Statements Of Cash Flows

v3.10.0.1
Consolidated Statements Of Cash Flows - USD ($)
12 Months Ended
Sep. 30, 2018
Sep. 30, 2017
OPERATING ACTIVITIES    
Net loss attributable to common stock holders before preferred stock dividend $ (23,938,389) $ (6,612,047)
Adjustments to reconcile net loss attributable to common stockholders before preferred stock dividend to net cash (used in) provided by operating activities:    
Depreciation and amortization 176,786 333,999
Amortization of intangible assets 275,262 147,009
Noncash interest expense 2,950,501  
Share-based compensation 1,638,505 756,275
Warrants issued   542,930
Deferred income taxes 630,150 (2,255,069)
Loss on settlement of accounts receivable 3,986,518  
Provision for obsolete inventory 90,856 345,179
Change in fair value of derivative liabilities (893,000)  
Other (2,756) 73,992
Changes in operating assets and liabilities, net of effects of acquisition of a business:    
Decrease in accounts receivable 1,874,555 7,277,349
Decrease (increase) in inventory 375,038 (479,418)
Increase in prepaid expenses and other assets (65,570) (77,520)
Increase in accounts payable 495,971 897,471
(Decrease) increase in unearned revenue (471,775) 1,014,517
Increase (decrease) in accrued expenses and other current liabilities 1,331,157 (981,779)
Net cash (used in) provided by operating activities (11,546,191) 982,888
INVESTING ACTIVITIES    
Aquisition of Aspen Park Pharmaceuticals   43,118
Capital expenditures (50,654) (133,486)
Net cash used in investing activities (50,654) (90,368)
FINANCING ACTIVITIES    
Proceeds from SWK credit agreement 10,000,000  
Payment of debt issuance costs (266,923)  
Installment payment on SWK credit agreement (642,485)  
Proceeds from sale of shares under common stock purchase agreement 3,000,000  
Payment of costs related to common stock purchase agreement (77,840)  
Proceeds from stock option exercises 66,000  
Net cash provided by financing activities 12,078,752  
Net increase in cash 481,907 892,520
CASH AT BEGINNING OF YEAR 3,277,602 2,385,082
CASH AT END OF YEAR 3,759,509 3,277,602
Supplemental disclosure of cash flow Information:    
Cash paid for income taxes 222,223 230,705
Schedule of noncash investing and financing activities:    
Issuance of common stock in connection with the APP Acquisition   1,826,097
Issuance of Series 4 Preferred Stock in connection with the APP Acquisition   17,981,883
Reduction of accrued expense upon issuance of shares   $ 22,176
Shares issued in connection with common stock purchase agreement 347,081  
Amortization of deferred costs related to common stock purchase agreement 84,984  
Increase in other assets from accounts payable and accrued expenses $ 190,000